Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
N02AA01 CHLORHYDRATE DE MORPHINE RENAUDIN G Morphine HCl - 20mg/ml 20mg/ml Injectable solution 1,100,607 L.L
J06BA02 CLAIRYG BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution 40,685,649 L.L
J06BA02 CLAIRYG BioHuman Human normal immunoglobulin G - 50mg/ml 10g/200ml Injectable solution 74,469,269 L.L
J06BA02 CUVITRU BioHuman Human normal immunoglobulin - 4g/20ml 200mg/ml Injectable solution 29,806,627 L.L
J06BA02 CUVITRU BioHuman Human normal immunoglobulin - 8g/40ml 200mg/ml Injectable solution 53,593,818 L.L
J01FF01 CLINDAMYCIN VIANEX BA FREE G Clindamycin (phosphate) - 600mg/4ml 600mg/4ml Injectable solution 201,576 L.L
J01FF01 CLINDAMYCIN-HAMELN G Clindamycin (phosphate) - 600mg/4ml 150mg/ml Injectable solution 3,535,650 L.L
C01EB10 CARDESINE G Adenosine - 6mg/2ml 6mg/2ml Injectable solution 563,070 L.L
L03AB07 CINNOVEX BioTech Interferon beta-1a - 30mcg 30mcg Injectable solution 39,804,728 L.L
J06BA02 CLAIRYG BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 200mg/100ml 200mg/100ml Injectable solution 5,120,040 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 200mg/100ml 200mg/100ml Injectable solution 5,120,040 L.L
L01FG02 CYRAMZA BioTech Ramucirumab - 500mg/50ml 500mg/50ml Injectable solution L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacin - 200mg/100ml 200mg/100ml Injectable solution 4,914,432 L.L
J01MA02 CIPROLON 200 G Ciprofloxacin (lactate) - 200mg/100ml 200mg/100ml Injectable solution 686,704 L.L
J01MA02 CIPROX G Ciprofloxacine (lactate) - 200mg/100ml 0.2%w/v Injectable solution 520,067 L.L
J01MA02 CEFLOXINE G Ciprofloxacin - 400mg/200ml 400mg/200ml Injectable solution 1,134,203 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 400mg/200ml 400mg/200ml (2mg/ml) Injectable solution 9,908,924 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 400mg/200ml 400mg/200ml Injectable solution 9,908,924 L.L
N05AF05 CLOPIXOL DEPOT B Zuclopenthixol decanoate - 200mg/ml 200mg/ml Injectable solution 512,004 L.L
N05AF05 CLOPIXOL ACUPHASE B Zuclopenthixol acetate - 100mg/2ml 100mg/2ml Injectable solution 857,372 L.L
D04AX CALAMINE PLUS B Diphenhydramine HCl - 0.25/100ml, Tetracaine HCl - 0.025/100ml, Zinc oxide - 8g/100ml, Calamine - 8g/100ml Lotion 177,899 L.L
R02A CHLORASEPTIC TOTAL SORE THROAT + COUGH LOZENGES WILD CHERRY G Benzocaine - 6mg, Dextromethorphan - 5mg, Menthol - 10mg Lozenge 537,537 L.L
D07AD01 CLOBEVAT G Clobetasol (propionate) - 0.05% 0.05% Ointment 302,045 L.L
G01AA10 CLINDAMYCIN G Clindamycin - 100mg 100mg Ovule 712,876 L.L
G03DA04 CYCLOGEST G Progesterone - 400mg 400mg Pessary 1,546,763 L.L
V03AE01 CALCIUM RESONIUM B Calcium Polystyrene Sulphonate - 15g 15g Powder 2,053,391 L.L
A06AB58 CITRAFLEET G Sodium picosulfate - 10mg/sachet, Magnesium oxide (light) - 3.5g/sachet, Citric acid (anhydrous) - 10.97g/sachet, Potassium - 195mg/sachet Powder for solution 1,191,988 L.L
J01DC04 CLORACEF FORTE G Cefaclor (monohydrate) - 250mg/5ml 250mg/5ml Powder for suspension 632,950 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 712,237 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025